---
title: "Weekly Recap | GlucoTrack -26.32%, dilution pressure trims midweek surge"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300188404.md"
description: "GlucoTrack (GCTK) fell 26.32% this week to close at $1.82, while the S&P 500 rose 1.21%, leaving it about 27.53 percentage points behind. The stock started the week quietly, with Monday (Sep 21) dropping to $2.30 and Tuesday holding near $2.22. Wednesday brought heavy volume and a dip to $1.998. Thursday saw a violent swing, spiking to $3.25 intraday before closing at $2.58. Friday gave back the gains and printed the week’s lowest close at $1.82. Weekly amplitude reached 58."
datetime: "2026-09-26T06:24:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300188404.md)
  - [en](https://longbridge.com/en/news/300188404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300188404.md)
generator: "portal-rs"
---

# Weekly Recap | GlucoTrack -26.32%, dilution pressure trims midweek surge

## The Week

GlucoTrack (GCTK) fell 26.32% this week to close at $1.82, while the S&P 500 rose 1.21%, leaving it about 27.53 percentage points behind. The stock started the week quietly, with Monday (Sep 21) dropping to $2.30 and Tuesday holding near $2.22. Wednesday brought heavy volume and a dip to $1.998. Thursday saw a violent swing, spiking to $3.25 intraday before closing at $2.58. Friday gave back the gains and printed the week’s lowest close at $1.82. Weekly amplitude reached 58.96% and average daily volume ran around 23.5 times the 60-day median. Churn between extremes dominated the tape.

## Key Events

The week’s story turned on a strategic update and fresh financing. On 23 Sep, GlucoTrack and Lōkahi Therapeutics outlined their post-merger focus: a targeted LT-100 clinical study and a wider university network for the ai² platform. A day later, Lōkahi’s ai² PIPELINE added Innovate GBM as an external partner, and GCTK briefly traded more than 80% higher across after-hours and premarket sessions. By Friday, the company priced a $3.1m registered direct offering and announced a debt-reducing public equity offering. The dilution overhang hit sentiment, with the stock sliding through premarket and regular trading back toward $1.82. A 424B5 filing confirmed the equity raise later that day.

## The Week Ahead

Macro data starts Monday with the Dallas Fed manufacturing business activity index (prior 11.6). Tuesday brings FHFA home prices, the Case Shiller 20-city index, JOLTS job openings, and consumer confidence. For a small-cap biotech, those liquidity signals can easily outweigh company-specific catalysts. On the corporate side, payout and use-of-proceeds details from the $3.1m offering remain the short-term focus, alongside any further updates on LT-100 development or new ai² collaborations.

## In Short

The strategic narrative pushed GCTK higher midweek, but the equity raise pulled it back below Monday’s open. The stock trades on negative book value and a TTM P/E near -0.08, reflecting an early-stage, cash-burning profile. On the latest trading day, large orders were net neutral, while medium and small orders showed modest net buying, a cautious tilt after the offering news. What matters now is not whether sentiment reignites, but how the fresh cash maps against clinical milestones before revenue arrives.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)

## Related News & Research

- [GlucoTrack Tightens Terms in Recent Financing Amendments](https://longbridge.com/en/news/300356119.md)
- [GlucoTrack Announces Debt-Reducing Public Equity Offering](https://longbridge.com/en/news/300081340.md)
- [Glucotrack Prices $3.1 Million Registered Direct Offering of Stock and Pre-Funded Warrants](https://longbridge.com/en/news/300078446.md)
- [GlucoTrack and Lōkahi Outline Post-Merger Strategic Focus](https://longbridge.com/en/news/299915641.md)
- [GlucoTrack unit Lōkahi Therapeutics expands ai² PIPELINE to external sponsor Innovate GBM](https://longbridge.com/en/news/299940538.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**